ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.
Last trade$239.02
Day change+$0.83 (+0.35%)
Day range$234.13 – $241.18
Volume527,834
Market cap$33.50B
OpenXNYS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$33.5B
Price / earnings
21.03×
Price / book
5.63×
Price / sales
5.84×
EV / sales
5.74×
EV / EBITDA
15.71×
Profitability
Earnings per share
$11.33
Return on assets
19.4%
Return on equity
26.79%
Dividend yield
1.07%
Liquidity and leverage
Debt / equity
0.07×
Current ratio
2.65×
Quick ratio
1.88×
Cash ratio
0.76×
Cash flow
Price / cash flow
18.92×
Price / free cash flow
20.82×
Free cash flow
$1.61B
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for RMD, quarterly periods
Line item
Q1 FY2027 Sep 30, 2026
Q4 FY2026 Jun 30, 2026
Q3 FY2026 Mar 31, 2026
Q2 FY2026 Dec 31, 2025
Q1 FY2026 Sep 30, 2025
Q4 FY2025 Jun 30, 2025
Q3 FY2025 Mar 31, 2025
Q2 FY2025 Dec 31, 2024
Revenue
$1.41B
$1.46B
$1.43B
$1.42B
$1.34B
$1.35B
$1.29B
$1.28B
Cost of revenue
$544.25M
$594.13M
$532.58M
$536.28M
$517.92M
$518.56M
$517.88M
$523.18M
Gross profit
$870.57M
$869.52M
$898.83M
$886.53M
$817.66M
$829.44M
$773.85M
$758.91M
Selling, general and administrative
$314.72M
$296.28M
$285.66M
$278.4M
$281.65M
$267.16M
$245.3M
$241.61M
Research and development
$102.86M
$105.73M
$94.27M
$90.97M
$89.48M
$86.44M
$83.94M
$81.37M
Total operating expenses
$417.58M
$420.81M
$399.02M
$394.87M
$371.13M
$374.9M
$347.59M
$341.67M
Operating income
$452.98M
$448.71M
$499.81M
$491.66M
$446.54M
$454.54M
$426.27M
$417.24M
Interest expense
-$4.81M
$20.89M
$12.29M
$0
-$7.12M
$5.76M
$793K
$0
Income before taxes
$539.16M
$474.16M
$502.31M
$496.15M
$446.79M
$458.05M
$417.69M
$418.32M
Income taxes
$120.74M
$90.73M
$103.58M
$103.56M
$98.26M
$78.35M
$52.65M
$73.7M
Net income
$418.41M
$383.43M
$398.73M
$392.59M
$348.54M
$379.71M
$365.04M
$344.62M
Net income attributable to common shareholders
$418.41M
$383.43M
$398.73M
$392.59M
$348.54M
$379.71M
$365.04M
$344.62M
EBITDA
$494.73M
$493.49M
$558.79M
$547.48M
$494.24M
$518.17M
$469.94M
$463.68M
Basic earnings per share
$2.93
$2.65
$2.74
$2.69
$2.38
$2.59
$2.49
$2.35
Diluted earnings per share
$2.92
$2.64
$2.74
$2.68
$2.37
$2.58
$2.48
$2.34
Recent news
Company coverage with links to the original publishers.
The American Academy of Sleep Medicine released a comprehensive report and multiyear roadmap to improve women's sleep health, identifying priority areas including fertility, pregnancy, postpartum health, menopausal transitions, and sleep disorders. The report highlights gaps in research, clinical care, and policy, calling for increased clinical trial representation, research funding, and tailored interventions for women.
Abbott reported Q3 2026 sales growth of 14.5% to $13.01 billion with broad-based strength across Established Pharmaceuticals, Medical Devices, and Diagnostics segments. The company announced plans to separate its Nutrition business into an independent publicly traded company by end of 2027. However, Abbott narrowed its 2026 sales growth guidance to 6% from 6.5-7.5% due to headwinds in Electrophysiology and Diabetes Care segments. The stock has outperformed peers and sector benchmarks over the past six months but is rated a Hold.
Inspire Medical Systems (INSP) shares gained 12.1% over three months despite a 7.9% revenue decline and 62.2% drop in adjusted Q3 EPS. Reimbursement issues cost the company $30M in Q3 revenues with a projected $120M full-year 2026 impact. The company targets low-single-digit revenue growth in 2027 through Project Horizon and battery replacement procedures, though reimbursement execution remains a key risk factor.
ResMed reported 7% core revenue growth in Q1 FY2027 with expanding gross margins driven by manufacturing productivity gains. The company noted that patients on GLP-1 obesity medications are 11% more likely to adopt CPAP therapy for sleep apnea and show higher retention rates. ResMed returned over $1 billion to shareholders this quarter through dividends and share repurchases following the sale of its MatrixCare business, reflecting confidence in its 2030 strategy targeting high single-digit revenue growth with higher earnings growth.
ResMed (RMD) delivered solid first-quarter fiscal 2027 results with adjusted EPS of $2.91, up 14% year-over-year and beating consensus by 9%. Revenues grew 6% to $1.41 billion, driven by sustained demand for sleep devices and masks. Gross margins expanded 50 basis points to 62.5% from productivity gains. However, the company faced headwinds from discontinued Astral life-support device sales and the MatrixCare divestiture. RMD maintained its fiscal 2027 guidance for 5-7% core constant-currency revenue growth and $12.00-$12.25 adjusted EPS.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
Ex-dividend
Amount / share
Pay date
Type
Nov 12, 2026
$0.66
Dec 17, 2026
recurring
Aug 20, 2026
$0.66
Sep 24, 2026
recurring
May 14, 2026
$0.60
Jun 18, 2026
recurring
Feb 12, 2026
$0.60
Mar 19, 2026
recurring
Nov 13, 2025
$0.60
Dec 18, 2025
recurring
Stock splits
Historical share-structure events and their execution dates.